The Biden administration on Tuesday named the first 10 medicines that will be subject to price negotiations between Medicare and participating drug companies.
“For far too long, pharmaceutical companies have made record profits while American families were saddled with record prices and unable to afford lifesaving prescription drugs,” U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra said in an agency news release announcing the list.
“Although drug companies are attempting to block Medicare from being able to negotiate for better drug prices, we will not be deterred. The Biden-Harris administration will continue working to ensure that Americans with Medicare have access to innovative, lifesaving treatments at lower costs,” Becerra added.
Millions of older Americans take these drugs, and enrollees of Medicare’s prescription drug program paid a total of $3.4 billion in out-of-pocket costs in 2022 for them, the HHS noted.
The Inflation Reduction Act of 2022 gave the federal government the explicit power to negotiate Medicare drug prices with pharmaceutical companies.
Reaction to the news of the list of medications was swift.
“This is a landmark day! Medicare has set the price for 10 drugs, sounding the alarm for drug companies,” Nick Fabrizio, a senior lecturer in health policy at Cornell University, said in a statement. “It could target 60 drugs by 2030… Call it negotiation or price control, but the government has just furthered on its promise to lower health care costs for all Americans.”
RELATED: How To Understand Medicare & All Of Its Benefits
But he offered up some caveats.
“Capping the cost of insulin for Medicare enrollees at $35 per month was the first shot across the bow,” he said. “Now the government looks to specific drugs that will have a greater impact on controlling costs. The implementation of these policy changes will take time to realize and are sure to be challenged in court, so we will have to see how much is saved and by when.”
Shortly after the list was announced, PhRMa released a statement condemning the move.
“Today’s announcement is the result of a rushed process focused on short-term political gain rather than what is best for patients. Many of the medicines selected for price setting already have significant rebates and discounts due to the robust private market negotiation that occurs in the Part D program today,” said Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen Ubl.
“Giving a single government agency the power to arbitrarily set the price of medicines with little accountability, oversight or input from patients and their doctors will have significant negative consequences long after this administration is gone,” Ubl added.
Here’s what you need to know about the drugs chosen for Medicare price negotiations: